報價延遲最少15分鐘:2026/06/02 20:59 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.21 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.29/-0.10
|
|
企業價值
315.68M
|
| 資產負債 |
|
每股賬面淨值
0.22
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
14.56M
|
|
每股收益
0.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank. |
